Garima Gupta, MD
Nephrology · Fort Wayne, INNPI 1073729125
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 93.7% of the total across 175 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 26 manufacturers, the largest accounting for just 21.7% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2022 at $959 and has fallen 65.7% since, to $328 in 2025.
Across 175 payments — averaging $19.33 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$734
- Akebia Therapeutics Inc$402
- Bayer$291
- Fresenius USA Marketing, Inc.$272
- Amgen$251
- Otsuka America Pharmaceutical, Inc.$242
- plus $1K from 20 others
Across 7 payments — averaging $94,927 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Novartis$483K
- Vertex$178K
- Bayer$3K
What the payments were for
- Food & beverage$3,17094%
- Education$2136%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca(2 entities) | 40 | $734 |
| Akebia Therapeutics Inc | 25 | $402 |
| Bayer | 19 | $291 |
| Fresenius USA Marketing, Inc. | 15 | $272 |
| Amgen(2 entities) | 16 | $251 |
| Otsuka America Pharmaceutical, Inc. | 11 | $242 |
| Vifor Pharma, Inc. | 10 | $223 |
| Mallinckrodt Hospital Products Inc. | 6 | $206 |
| Medtronic | 1 | $86 |
| Novartis | 5 | $85 |
| Incyte Corporation | 1 | $78 |
| Travere Therapeutics, Inc. | 5 | $76 |
| OPKO Pharmaceuticals, LLC | 4 | $73 |
| Nxstage Medical, Inc. | 1 | $72 |
| Boehringer Ingelheim | 3 | $54 |
| Ultragenyx Pharmaceutical Inc. | 2 | $35 |
| GSK | 2 | $30 |
| Novo Nordisk | 1 | $27 |
| Cormedix Inc. | 1 | $27 |
| Scpharmaceuticals Inc. | 1 | $25 |
| Kyowa Kirin, Inc. | 1 | $19 |
| Aurinia Pharma U.S., Inc. | 1 | $17 |
| Lexicon Pharmaceuticals, Inc. | 1 | $17 |
| Daiichi Sankyo Inc. | 1 | $16 |
| Ardelyx, Inc. | 1 | $14 |
| Mallinckrodt Enterprises LLC | 1 | $13 |
How this compares
$3,383 in reported general payments places this provider in the 75th percentile of 238 nephrology providers in Indiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| FarxigaDapagliflozin Propanediol | 86 | $77,395 |
| LokelmaSodium Zirconium Cyclosilicate | 51 | $35,834 |
| AuryxiaFerric Citrate | 13 | $19,826 |
| Sevelamer Carbonate | 101 | $18,308 |
| Lanthanum Carbonate | 14 | $6,418 |
| Cinacalcet Hcl | 24 | $4,455 |
| Clonidine | 12 | $2,999 |
| Calcitriol | 208 | $2,795 |
| Calcium Acetate | 24 | $1,993 |
| Losartan Potassium | 228 | $1,975 |
| Tacrolimus | 20 | $1,895 |
| Famotidine | 102 | $1,289 |
| Potassium Chloride | 62 | $1,159 |
| Midodrine Hcl | 18 | $919 |
| Bumetanide | 20 | $912 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AstraZenecaFarxiga, Lokelma | $734 | $113,229137 claims |
| Akebia Therapeutics IncAuryxia | $402 | $19,82613 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 238 nephrology providers in Indiana.
Other nephrology in Fort Wayne
- Andrew OshaughnessyFort Wayne$64K
- John DuckerFort Wayne$8K
- Melanie BarridoFort Wayne$6K
- Irfan MunirFort Wayne$5K
- Sajjad HabibFort Wayne$4K
- Kanakapura VenkatakrishnaFort Wayne$4K
- Kiran Mandya ChikkalingaiahFort Wayne$4K
- Prasanna IsaacFort Wayne$3K
- Guy AsherFort Wayne$3K
- Rajiv AgarwalIndianapolis$1.2M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.